President Xi supports COVID-19 waiver
01-06-2021
AIPPI weighs in on COVID waiver
17-05-2021
AstraZeneca sues Dr Reddy's over breast cancer drug
14-02-2017
Dr Reddy’s secures thrombosis drug rights in $17.5m deal
27-11-2015
Pavel Kapysh / Shutterstock.com
India-based generics drug maker Dr. Reddy's Laboratories has entered into a voluntary licensing agreement with Eli Lilly to expand access to COVID-19 treatment in India.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Dr Reddy’s, COVID-19, Biden, IP waiver, Eli Lilly, baricitinib, licensing
